Will taking Paxlovid for COVID affect one’s future immunity?


Dear Advice Team: In mid-July, I came down with COVID for the first time. I was vaccinated and had the first booster. I had symptoms: fever, headache, terrible sore throat and fatigue. My doctor had me take Paxlovid. I was COVID-positive for 12 days.

We’ve been told that getting COVID gives you some immunity from future exposures, at least for several months. But is the immunity boost less if you take Paxlovid than it would have been if your body fought off the virus completely on its own? Also, how long should I wait before getting the second booster? Can I assume I have protection for 4 to 6 months?

Welcome to Pandemic Problems, an advice column from The Chronicle’s engagement reporters that aims to help Bay Area residents solve their pandemic and post-pandemic conundrums — personal, practical or professional.

As COVID evolves into an endemic issue, we know readers are trying to navigate the “new normal.” Send your questions and issues to pandemicproblems@sfchronicle.com.

Today, The Chronicle’s Kellie Hwang fields this question from a reader wondering about immunity after taking Paxlovid.

Dear Reader: Paxlovid has been around for many months now, but some people still aren’t aware of the treatment and what it does, and who qualifies for it.

So first, a little background.

Paxlovid is an antiviral treatment made by Pfizer that treats mild to moderate COVID. It was granted emergency use authorization by the U.S. Food and Drug Administration in December for people 12 and older who test positive for COVID and are at high risk for developing severe illness. This category includes anyone over 50, or who is unvaccinated or has certain medical conditions such as lung or heart disease, diabetes or cancer, or is immunocompromised.

Paxlovid is given as a three-pill dose taken over five days, consisting of two different drugs. Nirmatrelvir inhibits a COVID protein to prevent the virus from replicating, and ritonavir slows nirmatrelvir from breaking down too quickly so it stays in the body longer, according to the FDA.

The initial Pfizer study showed Paxlovid reduced the risk of COVID hospitalization or death by 89%.



Read More: Will taking Paxlovid for COVID affect one’s future immunity?

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Live News

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.